Kyverna Therapeutics (KYTX) Treasury Shares (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Treasury Shares came in at $1.7 million in Q1 2026, up 169.18% YoY from $635167.0 in Q1 2025, and up 44.6% on a QoQ basis from $1.2 million in Q4 2025.
Kyverna Therapeutics (KYTX) Treasury Shares (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Treasury Shares data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Treasury Shares rose 169.18% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 169.18% YoY) and the FY2025 annual result came in at $1.2 million, up 115.37% from the prior year.
- Treasury Shares rose to $1.7 million in Q1 2026, from $1.2 million in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $114.6 million in Q3 2023 to a low of $544851.0 in Q3 2024.
- A 4-year average of $37.7 million and a median of $1.3 million in 2025 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2024 — Treasury Shares slumped 99.52% — and 2026, when it surged 169.18%.
- Tracing KYTX's Treasury Shares over 4 years: stood at $114.6 million in 2023, then plunged by 99.52% to $549001.0 in 2024, then soared by 115.37% to $1.2 million in 2025, then jumped by 44.6% to $1.7 million in 2026.
- The last three Treasury Shares figures came in at $1.7 million (Q1 2026), $1.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Mn |
| Jun 30, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.71 Mn |
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.29 Mn |
| Sep 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 635,167.00 |
| Mar 31, 2025 | 635,167.00 |
| Dec 31, 2024 | 549,001.00 |
| Dec 31, 2024 | 549,001.00 |
| Sep 30, 2024 | 544,851.00 |
| Sep 30, 2024 | 544,851.00 |
| Dec 31, 2023 | 114.56 Mn |
| Dec 31, 2023 | 114.56 Mn |
| Sep 30, 2023 | 114.56 Mn |
| Sep 30, 2023 | 114.56 Mn |